News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
MOUNTAIN VIEW, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced the presentation of positive safety, efficacy and quality of life results from the Company’s successfully completed Phase II CLEAR and CLASSIC clinical trials of avacopan in the treatment
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , April 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in April: H.C. Wainwright Global Life Sciences Conference Monday,
View HTML
Toggle Summary ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
-- Peer-reviewed findings show blocking CCR2 provides rapid and sustained renal benefit in well-established models of FSGS -- -- Improvements in renal function with CCR2 inhibition associated with encouraging histological changes, including increased podocyte density -- MOUNTAIN VIEW, Calif.
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
-- Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application -- -- Strengthened balance sheet with up to $100 million in new capital commitments;
View HTML
Toggle Summary ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference
MOUNTAIN VIEW, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 38 th Annual Health Care Conference on Tuesday March 13, 2018 at 10:40 a.m. ET .
View HTML
Toggle Summary ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
MOUNTAIN VIEW, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's fourth quarter 2017 financial results will be released before market open on Friday, March 9, 2018 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients --  -- Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium -- MOUNTAIN VIEW, Calif. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer
MOUNTAIN VIEW, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appointment of William (Bill) Fairey as Executive Vice President and
View HTML
Toggle Summary ChemoCentryx Secures up to $100 Million in New Capital Commitments
-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis -- -- Company Also Enters into $50 Million Growth Capital Financing Agreement with Hercules Capital -- MOUNTAIN
View HTML
Toggle Summary Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance ChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL
View HTML